What is the recommended dose for patients with CKD who initiate an OAC?
In patients with CKD who initiate OAC, concomitant antiplatelet therapy including low-dose aspirin is likely to substantially elevate bleeding risk and should be used very judiciously. The 110-mg dose is not available in the United States. Unless the patient is elderly or has high bleeding risk or is taking p-glycoprotein inhibitors, where dabigatran 110 mg bid is preferred, except in the United States, where the 110-mg dose is not available. Use 2.5 mg bid if 2 of 3 of the following criteria are present: age > 80 years, weight < 60 kg, or serum creatinine > 133 mmol/L. In the United States, caution is advised when CrCl is > 95 mL/min.